CRL

Business Context and Reporting Period

Company: Charles River Laboratories International, Inc. (CRL)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 28, 2026 (Fiscal Q1 2026)
Business Overview: A global non-clinical drug development partner providing research models, discovery and safety assessment services, and manufacturing solutions. The company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 1.2% year-over-year, driven by a 6.8% increase in Manufacturing revenue (Microbial Solutions) and a 0.7% increase in DSA revenue. RMS revenue declined 2.2% due to lower large and small model product sales.
• Operating Income Expansion: Operating income rose 60.6% to $119.9 million. This improvement was primarily due to a $38.5 million pre-tax gain on the sale of assets at the Wilmington, MA site, the absence of accelerated amortization expense seen in the prior year, and lower third-party legal costs. These gains were partially offset by higher acquisition and divestiture costs.
• Net Loss: The company reported a net loss of $14.8 million, a reversal from the $25.5 million net income in Q1 2025. The decline was principally caused by a $118.0 million pre-tax loss on assets held for sale related to the divestiture of CDMO and Cell Solutions businesses.
• Cash Flow: Operating cash flow decreased significantly to $41.1 million from $171.7 million in the prior year, largely due to higher payments for variable compensation (annual bonuses) and changes in working capital.

Guidance, Outlook, Risks, and Unusual Items

Acquisitions and Divestitures

• Acquisitions: Completed the acquisition of K.F. Cambodia Ltd (NHP supplier) for $507.3 million (including deferred consideration) and acquired 100% of PathoQuest SAS for approximately $60.0 million.
• Divestitures: Signed an agreement to sell European Discovery Services to IQVIA for $145.0 million. Completed the sale of CDMO and Cell Solutions businesses to GI Partners, recognizing a $118.0 million pre-tax loss in Q1 2026. The final loss on sale will be determined in Q2 2026.

Management Commentary and Outlook

• Market Environment: Management notes a cautious spending environment, particularly in the DSA segment. DSA backlog remained consistent at $1.9 billion.
• Cost Savings: The company is implementing efficiency initiatives expected to generate approximately $300 million in cumulative, annualized cost savings by the end of 2026.
• Capital Allocation: The company repurchased 1.1 million shares for $200.0 million under a $1.0 billion program, with $800.0 million remaining.

Risks and Contingencies

• Litigation: A securities class action regarding NHP importation disclosures was reversed in part by the First Circuit Court of Appeals and returned to District Court. Two derivative lawsuits remain stayed pending the class action outcome. The company cannot estimate potential exposure.
• Cybersecurity: The company disclosed a recent social engineering attack involving unauthorized access to employee credentials. The incident was contained, and no material disruption to financial systems or operations was reported, though the extent of data exfiltration is being assessed.
• Tax Rate: The effective tax rate was 50.6% in Q1 2026 compared to 28.1% in Q1 2025, primarily due to the tax effects of the divestiture loss and accrued interest on uncertain tax positions.

Investor Verification Checklist

• Divestiture Final Loss: Verify the final loss on the CDMO and Cell Solutions divestiture to be recognized in Q2 2026, as the $118.0 million recorded in Q1 is preliminary.
• Acquisition Integration: Monitor the integration progress and financial impact of the $507.3 million Cambodian NHP supplier acquisition.
• Litigation Status: Track developments in the securities class action and derivative lawsuits regarding NHP importation disclosures.
• Cybersecurity Impact: Confirm the final assessment of the recent social engineering attack regarding any potential data breaches or regulatory fines.
• Working Capital Trends: Analyze the sustainability of operating cash flows given the significant drop in Q1 2026 due to bonus payments and working capital changes.